• Consensus Rating: Hold
  • Consensus Price Target: $12.00
  • Forecasted Upside: 26.32%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$9.50
+0 (0.00%)

This chart shows the closing price for MDRX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Veradigm Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MDRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MDRX

Analyst Price Target is $12.00
▲ +26.32% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Veradigm in the last 3 months. The average price target is $12.00, with a high forecast of $15.00 and a low forecast of $10.00. The average price target represents a 26.32% upside from the last price of $9.50.

This chart shows the closing price for MDRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 6 contributing investment analysts is to hold stock in Veradigm. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
12/31/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
3/31/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
6/29/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
9/27/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
12/26/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
3/25/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
5/24/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings
6/23/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/28/2024TD CowenLower TargetBuy ➝ Buy$26.00 ➝ $15.00Low
3/19/2024Deutsche Bank AktiengesellschaftReiterated RatingBuy ➝ Hold$15.00 ➝ $10.00Low
1/19/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$22.00 ➝ $11.00Low
1/3/2024BarclaysInitiated CoverageEqual Weight$11.00Low
11/14/2023StephensReiterated RatingEqual Weight ➝ Equal Weight$13.00Low
10/10/2023StephensReiterated RatingEqual Weight ➝ Equal Weight$13.00Low
7/6/2023ArgusDowngradeBuy ➝ HoldLow
6/30/2023Deutsche Bank AktiengesellschaftLower Target$21.00 ➝ $18.00Low
4/11/2023StephensInitiated CoverageEqual Weight$13.00Low
3/1/2023SVB SecuritiesLower Target$24.00 ➝ $17.00Low
2/1/2023Piper SandlerDowngradeOverweight ➝ Neutral$17.00 ➝ $18.50Low
12/7/2022ArgusUpgradeHold ➝ Buy$26.00Low
11/18/2022JPMorgan Chase & Co.Boost TargetUnderweight$19.00 ➝ $20.00Low
11/8/2022The Goldman Sachs GroupUpgradeNeutral ➝ Buy$22.00 ➝ $23.00Low
11/4/2022Piper SandlerReiterated RatingOverweight$17.00Low
9/15/2022KeyCorpInitiated CoverageSector Weight ➝ Sector WeightLow
7/12/2022The Goldman Sachs GroupInitiated CoverageNeutral$21.00N/A
6/9/2022Piper SandlerLower Target$19.00 ➝ $17.00Medium
5/6/2022Piper SandlerLower Target$22.00 ➝ $19.00High
3/18/2022Piper SandlerBoost TargetNeutral$19.00 ➝ $22.00High
3/4/2022Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$20.00 ➝ $26.00Medium
3/3/2022SVB LeerinkBoost TargetOutperform$22.00 ➝ $24.00Medium
1/25/2022SVB LeerinkUpgradeMarket Perform ➝ Outperform$19.00 ➝ $22.00High
1/25/2022Piper SandlerBoost Target$17.00 ➝ $19.00High
11/23/2021Deutsche Bank AktiengesellschaftBoost TargetHold$18.00 ➝ $20.00Low
11/5/2021Cantor FitzgeraldReiterated RatingNeutralMedium
8/6/2021Piper SandlerReiterated RatingIn-Line ➝ Neutral$15.00 ➝ $17.00Low
8/6/2021SVB LeerinkBoost TargetMarket Perform$17.00 ➝ $19.00High
8/6/2021Royal Bank of CanadaBoost TargetOutperform$17.00 ➝ $19.00High
5/26/2021SVB LeerinkBoost TargetMarket Perform$16.00 ➝ $17.00Medium
5/20/2021Deutsche Bank AktiengesellschaftBoost TargetHold$15.00 ➝ $17.00Low
4/30/2021SVB LeerinkBoost TargetMarket Perform$15.00 ➝ $16.00Low
4/29/2021JPMorgan Chase & Co.Initiated CoverageUnderweightLow
3/8/2021ArgusReiterated RatingBuy ➝ HoldN/A
3/2/2021ArgusDowngradeBuy ➝ HoldHigh
2/26/2021SVB LeerinkLower TargetMarket Perform$16.00 ➝ $15.00High
2/26/2021Piper SandlerLower TargetNeutral$17.00 ➝ $15.00High
2/16/2021Piper SandlerBoost TargetNeutral$11.50 ➝ $17.00Low
11/25/2020Bank of AmericaBoost TargetBuy$14.00 ➝ $16.50Low
11/11/2020ArgusUpgradeHold ➝ Buy$14.00Low
10/23/2020JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$9.00 ➝ $11.00Low
10/19/2020Robert W. BairdDowngradeOutperform ➝ Neutral$13.00High
10/14/2020Cantor FitzgeraldBoost TargetNeutral$9.00 ➝ $13.00High
10/14/2020SVB LeerinkBoost TargetMarket Perform$10.00 ➝ $13.00High
8/24/2020JPMorgan Chase & Co.Boost TargetNeutral$8.00 ➝ $9.00Low
8/11/2020Morgan StanleyBoost TargetUnderweight$6.00 ➝ $8.00High
8/3/2020Royal Bank of CanadaBoost TargetOutperform$8.00 ➝ $10.00High
7/31/2020Cantor FitzgeraldBoost TargetHold ➝ Neutral$6.00 ➝ $9.00High
7/31/2020SVB LeerinkBoost TargetMarket Perform$6.00 ➝ $10.00Low
7/21/2020The Goldman Sachs GroupDowngradeNeutral ➝ Sell$6.50 ➝ $5.50High
6/11/2020Deutsche Bank AktiengesellschaftLower TargetHold$11.00 ➝ $9.00High
5/13/2020Morgan StanleyBoost TargetUnderweight$5.00 ➝ $6.00Low
5/13/2020SunTrust BanksBoost TargetHold$6.00 ➝ $7.00High
5/10/2020Royal Bank of CanadaReiterated RatingBuy$8.00Low
5/8/2020SVB LeerinkLower TargetMarket Perform$8.00 ➝ $6.00Medium
5/8/2020Cantor FitzgeraldReiterated RatingNeutral$8.00 ➝ $6.00High
4/22/2020Jefferies Financial GroupDowngradeBuy ➝ Hold$10.50 ➝ $7.00High
4/20/2020Royal Bank of CanadaInitiated CoverageOutperform$8.00Medium
4/13/2020SVB LeerinkInitiated CoverageMarket Perform$8.00High
3/5/2020SunTrust BanksLower TargetHold$11.00 ➝ $9.00High
3/4/2020Deutsche Bank AktiengesellschaftLower TargetHold$12.00 ➝ $11.00High
3/3/2020Dougherty & CoReiterated RatingBuyHigh
3/3/2020Piper SandlerLower Target$12.00 ➝ $9.50High
3/3/2020CfraLower TargetStrong Sell$9.00 ➝ $6.00Medium
3/3/2020Robert W. BairdLower TargetOutperform$13.00 ➝ $10.00High
3/3/2020Cantor FitzgeraldReiterated RatingNeutral$11.00 ➝ $8.00High
11/26/2019UBS GroupInitiated CoverageNeutral$11.50Low
11/5/2019Cantor FitzgeraldReiterated RatingNeutralMedium
9/26/2019Deutsche Bank AktiengesellschaftInitiated CoverageHold$11.00Low
8/23/2019Jefferies Financial GroupInitiated CoverageBuy$13.00High
8/12/2019Robert W. BairdSet TargetBuy$13.00Medium
8/11/2019Evercore ISIReiterated RatingHold$11.50Low
(Data available from 6/24/2019 forward)

News Sentiment Rating

0.57 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/27/2023
  • 5 very positive mentions
  • 21 positive mentions
  • 10 negative mentions
  • 4 very negative mentions
12/27/2023
  • 5 very positive mentions
  • 16 positive mentions
  • 4 negative mentions
  • 2 very negative mentions
1/26/2024
  • 9 very positive mentions
  • 4 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
2/25/2024
  • 11 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/26/2024
  • 5 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/25/2024
  • 7 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/25/2024
  • 10 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/24/2024

Current Sentiment

  • 10 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Veradigm logo
Veradigm Inc., a healthcare technology company, provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records (EHR), information connectivity, private cloud hosting, outsourcing, analytics, patient access, and population health management solutions. The company operates through two segments, Hospitals and Large Physician Practices, and Veradigm. The Hospitals and Large Physician Practices segment provides integrated clinical and financial management solutions, which primarily include EHR-related software; and related installation, support and maintenance, outsourcing, private cloud hosting, and revenue cycle management services. The Veradigm segment offers payer and life sciences solutions, which are primarily targeted at payers, life sciences companies, and other healthcare stakeholders; and software applications for patient engagement and EHR software to single-specialty, and small and mid-sized physician practices, including related clinical, financial, administrative, and operational solutions. Its solutions enable clients to transition, analyze, and coordinate care, and enhance the healthcare delivery across the care community. The company serves physicians, hospitals, governments and militaries, health systems, health plans, life-sciences companies, retail clinics, surgery centers, retail pharmacies, pharmacy benefit managers, insurance companies, employer wellness clinics, consumers, lab companies, urgent care facilities, and venture capital firms, as well as post-acute organizations, such as home health and hospice agencies. The company was formerly known as Allscripts Healthcare Solutions, Inc. and changed its name to Veradigm Inc. in January 2023. Veradigm Inc. was founded in 1986 and is headquartered in Chicago, Illinois.
Read More

Today's Range

Now: $9.50
Low: $9.50
High: $10.00

50 Day Range

MA: $8.38
Low: $7.45
High: $9.76

52 Week Range

Now: $9.50
Low: $5.01
High: $14.09

Volume

85,100 shs

Average Volume

2,726,928 shs

Market Capitalization

$1.04 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.68

Frequently Asked Questions

What sell-side analysts currently cover shares of Veradigm?

The following Wall Street sell-side analysts have issued reports on Veradigm in the last year: Argus, Barclays PLC, Deutsche Bank Aktiengesellschaft, Royal Bank of Canada, Stephens, StockNews.com, and TD Cowen.
View the latest analyst ratings for MDRX.

What is the current price target for Veradigm?

5 Wall Street analysts have set twelve-month price targets for Veradigm in the last year. Their average twelve-month price target is $12.00, suggesting a possible upside of 26.3%. TD Cowen has the highest price target set, predicting MDRX will reach $15.00 in the next twelve months. Deutsche Bank Aktiengesellschaft has the lowest price target set, forecasting a price of $10.00 for Veradigm in the next year.
View the latest price targets for MDRX.

What is the current consensus analyst rating for Veradigm?

Veradigm currently has 4 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in MDRX, but not buy more shares or sell existing shares.
View the latest ratings for MDRX.

What other companies compete with Veradigm?

Other companies that are similar to Veradigm include Omnicell, HealthStream, NextGen Healthcare, Ebix and Cortexyme. Learn More about companies similar to Veradigm.

How do I contact Veradigm's investor relations team?

Veradigm's physical mailing address is 222 MERCHANDISE MART PLAZA SUITE 2024, CHICAGO IL, 60654. The software maker's listed phone number is (800) 334-8534 and its investor relations email address is [email protected]. The official website for Veradigm is www.allscripts.com. Learn More about contacing Veradigm investor relations.